Tuberous sclerosis medical therapy: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Tuberous sclerosis}} {{CMG}} ==Medical Therapy== Drug therapy for some of the manifestations of TSC is currently in the developmental stage.<ref>{{cite journal |...")
 
No edit summary
Line 5: Line 5:
==Medical Therapy==
==Medical Therapy==


Drug therapy for some of the manifestations of TSC is currently in the developmental stage.<ref>{{cite journal | pmid = 16868562 | doi=10.1038/sj.ejhg.5201625 | volume=14 | issue=10 | title=Tuberous sclerosis | year=2006 | month=October | author=Yates JR | journal=Eur. J. Hum. Genet. | pages=1065–73}}</ref> For example, a 2008 study found that treatment with [[rapamycin]] rescued learning and memory deficits in a mouse model of tuberous sclerosis.<ref>{{cite journal |journal= Nat Med |year=2008 |title= Reversal of learning deficits in a Tsc2+/− mouse model of tuberous sclerosis |author= Ehninger D, Han S, Shilyansky C ''et al.'' |doi=10.1038/nm1788 |pmid=18568033 |laysummary=http://www.sciencedaily.com/releases/2008/06/080622224428.htm |laysource= Science News |laydate=23 June 2008 |volume= 14 |pages= 843–8 |issue= 8 |pmc= 2664098}}</ref> [[Community TSC]] is a distributed computing project to find drugs to treat TSC.{{Citation needed|date=June 2008|laysummary=http://www.childhooddiseases.org/community_tsc.html}}
=== Epilepsy ===
The patients usually have relapse of symptoms in the clinical course. Unless any vital function is affected, life expectancy is good. Majority of patients will require some medications to control symptoms, e.g., anti-epileptics to control seizures.
In 2010 [[everolimus]] was approved for the treatment of [[subependymal giant cell astrocytoma]].


Other drugs used include:
* Anti-[[seizure]] medications can be prescribed to control [[seizures]]. The preferred medication is [[vigabatrin]]<ref name="pmid19557123">{{cite journal |author=Tsao CY |title=Current trends in the treatment of infantile spasms |journal=Neuropsychiatr Dis Treat |volume=5 |issue= |pages=289–99 |year=2009 |pmid=19557123 |pmc=2695218 |doi= |url=http://www.dovepress.com/articles.php?article_id=3150}}</ref>, but other [[anticonvulsants]], [[clobazam]], [[Ketogenic diet|ketogenic]] diet, [[vagal nerve stimulation]] or surgical resection of CNS lesion responsible for the [[epilepsy]].<ref name=":0">Henske, Elizabeth P., et al. "Tuberous sclerosis complex." ''Nature reviews Disease primers'' 2.1 (2016): 1-18.</ref> Treatment before the onset of [[epilepsy]] and other neuropsychiatric manifestations may be beneficial, but trials testing this approach are still ongoing (EPISTOP trial). [[mTOR]] inhibitors may present with some anti-epileptogenic properties.<ref name=":0" />
* [[Vigabatrin]]<ref name="pmid19557123">{{cite journal |author=Tsao CY |title=Current trends in the treatment of infantile spasms |journal=Neuropsychiatr Dis Treat |volume=5 |issue= |pages=289–99 |year=2009 |pmid=19557123 |pmc=2695218 |doi= |url=http://www.dovepress.com/articles.php?article_id=3150}}</ref>
 
* [[ACTH]]<ref name="Shorvon2010">{{cite book|author=Simon D. Shorvon|title=Handbook of Epilepsy Treatment|url=http://books.google.com/books?id=ce1YGxllLsgC&pg=PA93|accessdate=11 October 2010|year=2010|publisher=John Wiley and Sons|isbn=978-1-4051-9818-9|pages=93–}}</ref>
=== Lymphangioleiomyomatosis ===
 
* [[Sirolimus]] should be used in women presenting with TSC-associated [[lymphangioleiomyomatosis]] or sporadic LAM with <70% of the predicted normal FEV1. [[Everolimus]] has also been show to improve these patients' condition.<ref name=":0" />
 
=== Angiomyolipoma ===
 
* Treatment is done in a pre-emptive manner to prevent bleeding, reduce tumor size or slow its growth. Percutaneous [[Therapeutic embolization|embolization]] (which may present with postembolization syndrome), systemic [[everolimus]] (preferred method) and nephron-sparing surgical resection are possible treatments.<ref name=":0" />
 
=== Subependymal Giant Cell Astrocytoma ===
 
* Surgical resection is the most performed treatment, but may complicate with incomplete resection, hemorrhage, infection and cerebrospinal fluid obstruction.<ref name=":0" /> Due to these complications, treatment with [[mTOR]] inhibitors have been recommended, being well tolerated and presenting with side effects that decreases over time.<ref name=":0" />
 
=== Tuberous Sclerosis Complex-associated Neuropsychiatric Disorder ===
 
* There are no specific interventions, patients must be followed closely by a psychiatrist. Trials exploring the use of [[mTOR]] inhibitors for this manifestation are ongoing.<ref name=":0" />
 
=== Skin Lesions ===
For TSC-associated skin lesions, the following treatments may be performed:
 
* [[Sunscreen|Sun protection]];
* Ablation with pulse laser dye or [[CO2]];
* Surgery
* "Camouflage make-up"
* Topical mTOR inhibitors.
 
=== mTOR Inhibitors side effect: ===
mTOR inhibition therapy may cause [[stomatitis]], [[Diabetes mellitus|diabetes]], [[hyperlipidemia]], wound-healing complications, infertility and delayed sexual maturation.<ref name=":0" />


==References==
==References==

Revision as of 23:13, 19 June 2020

Tuberous sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Differentiating Tuberous sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tuberous sclerosis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Tuberous sclerosis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tuberous sclerosis medical therapy

CDC on Tuberous sclerosis medical therapy

Tuberous sclerosis medical therapy in the news

Blogs on Tuberous sclerosis medical therapy

Directions to Hospitals Treating Tuberous sclerosis

Risk calculators and risk factors for Tuberous sclerosis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Medical Therapy

Epilepsy

Lymphangioleiomyomatosis

Angiomyolipoma

  • Treatment is done in a pre-emptive manner to prevent bleeding, reduce tumor size or slow its growth. Percutaneous embolization (which may present with postembolization syndrome), systemic everolimus (preferred method) and nephron-sparing surgical resection are possible treatments.[2]

Subependymal Giant Cell Astrocytoma

  • Surgical resection is the most performed treatment, but may complicate with incomplete resection, hemorrhage, infection and cerebrospinal fluid obstruction.[2] Due to these complications, treatment with mTOR inhibitors have been recommended, being well tolerated and presenting with side effects that decreases over time.[2]

Tuberous Sclerosis Complex-associated Neuropsychiatric Disorder

  • There are no specific interventions, patients must be followed closely by a psychiatrist. Trials exploring the use of mTOR inhibitors for this manifestation are ongoing.[2]

Skin Lesions

For TSC-associated skin lesions, the following treatments may be performed:

  • Sun protection;
  • Ablation with pulse laser dye or CO2;
  • Surgery
  • "Camouflage make-up"
  • Topical mTOR inhibitors.

mTOR Inhibitors side effect:

mTOR inhibition therapy may cause stomatitis, diabetes, hyperlipidemia, wound-healing complications, infertility and delayed sexual maturation.[2]

References

  1. Tsao CY (2009). "Current trends in the treatment of infantile spasms". Neuropsychiatr Dis Treat. 5: 289–99. PMC 2695218. PMID 19557123.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 2.6 2.7 Henske, Elizabeth P., et al. "Tuberous sclerosis complex." Nature reviews Disease primers 2.1 (2016): 1-18.